Literature DB >> 8353070

Drugs ten years later: epirubicin.

G Bonadonna1, L Gianni, A Santoro, V Bonfante, P Bidoli, P Casali, R Demicheli, P Valagussa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8353070     DOI： 10.1093/oxfordjournals.annonc.a058514

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  23 in total

1.  Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.

Authors:  W Scheithauer; G Kornek; M Raderer; K Koperna-Mach; C Müller; J Karner; J Kastner; C Tetzner
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

2.  Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.

Authors:  P Schütt; K Zimmermann; C Derks; P Ebeling; A Welt; M Poser; J Hense; K Metz; J Anhuf; M Sandmann; M Neise; T Moritz; M Stuschke; N Niederle; S Seeber; Mohammad R Nowrousian
Journal:  J Cancer Res Clin Oncol       Date:  2008-08-29       Impact factor: 4.553

Review 3.  Anthracyclines: cardiotoxicity and its prevention.

Authors:  J P Hale; I J Lewis
Journal:  Arch Dis Child       Date:  1994-11       Impact factor: 3.791

4.  Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS).

Authors:  W Stöhr; M Paulides; I Brecht; A Kremers; J Treuner; T Langer; J D Beck
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-05       Impact factor: 4.553

5.  MicroRNA-130a reduces drug resistance in breast cancer.

Authors:  Jin Huang; Min Zhao; Hongguang Hu; Jin Wang; Lin Ang; Li Zheng
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

6.  A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer.

Authors:  D Rischin; L K Webster; M J Millward; G C Toner; S Nawaratne; V Ganju; P Francis; J F Bishop
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

7.  Chemotherapy for breast cancer in pregnancy: evidence and guidance for oncologists.

Authors:  Sophie E McGrath; Alistair Ring
Journal:  Ther Adv Med Oncol       Date:  2011-03       Impact factor: 8.168

Review 8.  Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.

Authors:  D Ormrod; K Holm; K Goa; C Spencer
Journal:  Drugs Aging       Date:  1999-11       Impact factor: 3.923

9.  No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma.

Authors:  C Bokemeyer; B Kynast; A Harstrick; E Laage; E Schmoll; P von Wussow; H J Schmoll
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy.

Authors:  Jae Hong Seo; Hwa Jung Sung; Kyong Hwa Park; In Keun Choi; Sang Cheul Oh; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim; Ae-Ree Kim; Jae-Bok Lee; Bum Hwan Koo
Journal:  Invest New Drugs       Date:  2008-08-29       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.